BETTY SIZEMORE: Open Payments
NPI 1215333133 · MANCHESTER, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$828 in 48 payments from 11 companies in 2025. Trend: 2023 $1,085 · 2024 $885 · 2025 $828
Food & beverage: $828
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $249 |
| AstraZeneca Pharmaceuticals LP | 5 | $169 |
| Novo Nordisk Inc | 11 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Ardelyx, Inc. | 2 | $32 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| Lilly USA, LLC | 2 | $32 |
| Verona Pharma, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $15 |
Products named: VRAYLAR, FARXIGA, Ozempic, CAPLYTA, QULIPTA, Rybelsus, SPRAVATO, IBSRELA.
Industry payments across KY — which companies pay providers there.
